CHICAGO — OCT accurately staged skin cancers, allowing for better diagnosis of basal cell carcinoma, prediction of margins and improved planning for Mohs surgery, according to a study presented here.
“Mohs surgery is considered the gold standard for treating high-risk basal cell, yet as we all know, it’s not a perfect system. For one thing, it’s expensive. For another, it’s time consuming,” Sruti S. Akella, MD, of the University of Illinois Eye and Ear Infirmary, Chicago, said at the ASOPRS Fall Scientific Symposium. “Finally, it can be unpredictable.